Welcome to our dedicated page for Koru Med Sys SEC filings (Ticker: KRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for KORU Medical Systems, Inc. (NASDAQ: KRMD), a medical technology company focused on large-volume subcutaneous infusion solutions. These regulatory documents offer detailed information on the company’s operations, financial condition, risk factors, and material agreements related to its Freedom Syringe Infusion System and associated businesses.
Through its periodic reports, such as Form 10-K annual reports and Form 10-Q quarterly reports, KORU Medical discloses audited and interim financial statements, segment information for its core business and Pharma Services and Clinical Trials activities, and discussions of factors affecting demand for its subcutaneous infusion devices and services. These filings also describe the structure of the Freedom System, its regulatory status, and the company’s role in supporting large-volume subcutaneous drug delivery.
Form 8-K current reports document material events, including the public release of financial results, updated guidance, and key contracts. Recent 8-K filings have referenced press releases on preliminary and quarterly financial results and an Amended and Restated Manufacturing and Supply Agreement with Command Medical Products, Inc., which covers the manufacture and supply of subassemblies, needle sets, and tubing products for KORU Medical.
Investors can also review proxy statements for information on executive compensation, equity awards, and corporate governance, as well as Form 4 insider transaction reports that show purchases, sales, or grants of KORU Medical common stock by directors and officers under the KRMD ticker.
On Stock Titan, KORU Medical’s SEC filings are updated as new documents are posted to the SEC’s EDGAR system. AI-powered tools can summarize lengthy filings such as 10-Ks and 10-Qs, highlight key sections on revenue drivers, manufacturing and supply arrangements, and non-GAAP metrics like adjusted EBITDA, and help users quickly locate discussions of regulatory submissions, pharma collaborations, and other factors relevant to KRMD’s subcutaneous infusion business.
KORU Medical Systems, Inc. amended its loan and security agreement with HSBC Ventures USA Inc. covering a $5,000,000 revolving credit facility and a $5,000,000 term loan. The company has not drawn on this credit facility and is not required to do so.
The amendment extends the revolver maturity from December 31, 2026 to March 30, 2028 and the term loan maturity from December 1, 2028 to December 1, 2029. It also extends the term loan interest-only period to June 30, 2027, with a possible extension to December 31, 2027 if certain EBITDA milestones are met, lowers the interest rate floor to 5.50% from 6.50%, removes the adjusted quick ratio covenant, and adds a remaining months liquidity covenant of at least twelve months once the revolver is drawn.
Matin Shahriar reported acquisition or exercise transactions in this Form 4 filing.
KORU Medical Systems director Matin Shahriar received a compensation-related grant of 3,472 shares of common stock at an indicated value of $4.32 per share. After this award, he directly holds 97,573 common shares. This was an equity grant, not an open-market stock purchase or sale.
French Donna reported acquisition or exercise transactions in this Form 4 filing.
KORU Medical Systems director Donna French received a grant of Common Stock reported in a Form 4. She was awarded 3,472 shares at a value of $4.32 per share as a compensation-related grant, not an open-market purchase. Following this award, she directly holds 94,943 shares of KORU Medical Systems common stock.
KORU Medical Systems director Edward Wholihan received an award of 3,472 shares of Common Stock of KORU Medical Systems, Inc. The shares were granted at a price of $4.32 per share and are reported as directly owned.
Following this grant, Wholihan now directly holds 47,741 shares of Common Stock. This was recorded as a grant, award, or other acquisition on a Form 4 insider transaction report, rather than an open-market purchase or sale.
KORU Medical Systems director Robert Cascella received a stock grant, increasing his direct holdings. He was awarded 3,472 shares of Common Stock as a grant or award at an indicated price of $4.32 per share. Following this compensation-related acquisition, he directly owns 94,584 shares. This is a routine equity award rather than an open-market purchase or sale.
FLETCHER R JOHN reported acquisition or exercise transactions in this Form 4 filing.
KORU Medical Systems director R. John Fletcher received an equity grant of common stock. On the reported date, he was awarded 5,208 shares of KORU Medical Systems, Inc. common stock at an indicated value of $4.32 per share, reflecting compensation rather than an open-market purchase. Following this grant, he directly holds a total of 226,800 common shares, aligning his interests further with other shareholders.
Manko Joseph M. Jr. reported acquisition or exercise transactions in this Form 4 filing.
KORU Medical Systems insiders reported a new share award. On March 31, 2026, Horton Capital Partners Fund, L.P., a 10% owner, received a grant of 3,472 shares of KORU Medical Systems common stock at no cost, increasing its indirectly held position to 5,065,970 shares.
The filing also shows a separate direct holding of 500,200 common shares reported by the insider group as of the same date, providing context for their overall ownership stake.
KORU Medical Systems reported that its President and Chief Commercial Officer, Adam R. Kalbermatten, received new equity awards as part of his compensation. He was granted 45,098 restricted stock units and 45,098 performance stock units, each representing the right to receive one share of common stock upon vesting.
The restricted stock units vest in equal annual installments beginning on March 17, 2027. The performance stock units vest based on achievement of performance conditions measured as of December 31, 2028, with potential payout ranging from 0% to 150% of the 45,098 target units, or fully upon a change in control before that date.
He also received options to buy 67,779 shares of common stock at an exercise price of $4.35 per share, expiring on March 17, 2036. All transactions are grants or awards, not open-market purchases or sales.
KORU Medical Systems, Inc. Chief Operating Officer Christopher Pazdan reported several equity compensation transactions. He received 5,064 shares of common stock from vested restricted stock units, with 1,628 shares withheld to cover tax obligations, leaving 3,436 shares held directly.
On the same grant date, he was awarded 31,226 restricted stock units that vest in equal increments on March 17, 2027 and each first, second, and third anniversary of that date, and 31,226 performance stock units that can pay out between 0% and 150% of target based on performance as of December 31, 2028, or fully upon a change in control before then. He also received an option to buy 46,929 shares of common stock at an exercise price of $4.35 per share, expiring on March 17, 2036. All events are compensation-related and do not involve open-market buying or selling.
KORU Medical Systems reported several equity transactions for Chief Financial Officer Thomas Edward Adams. He received grants of 38,918 restricted stock units and 38,918 performance stock units, each representing the right to receive one share of common stock upon vesting. The restricted stock units were granted under the 2024 Omnibus Equity Incentive Plan and vest in equal increments on March 17, 2027 and on the first, second and third anniversaries of that date. The performance stock units are tied to performance through December 31, 2028, with potential payout between 0% and 150% of the 38,918-share target, and they vest in full at the reported amount upon a change in control before that date. Adams also received an option to buy 58,490 shares of common stock at an exercise price of $4.35 per share, expiring on March 17, 2036. In a related event, 5,404 shares of common stock were issued upon vesting of restricted stock units, and 2,123 of those shares were withheld at $4.28 per share to satisfy tax obligations, leaving 3,281 shares held directly.